Picard Medical Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Core Viewpoint - Picard Medical, Inc. is actively participating in key healthcare conferences, highlighting its leadership in total artificial heart technology and its commitment to advancing medical innovation [1][4]. Group 1: Conference Participation - Picard Medical will attend the 44th Annual J.P. Morgan Healthcare Conference, including events such as LifeSci Advisors' Corporate Access Event and Lifeblood and Goodwin's CEO-Only MedTech Forum [1]. - The Lifeblood and Goodwin's MedTech CEO-Only Forum is scheduled for January 12, 2026, as an invite-only discussion forum in San Francisco, CA [3]. - The LifeSci Advisors 15th Annual Corporate Access Event will take place on January 14, 2026, featuring one-on-one meetings at The Beacon Grand, San Francisco, CA [3]. Group 2: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for its SynCardia Total Artificial Heart (STAH), the only commercially available total artificial heart technology for patients with end-stage heart failure [4]. - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it is the only commercially available artificial heart in the United States and Canada [4]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [4].